🔬 “Aspen Neuroscience looks to combine its expertise in stem cell biology, genomics and neurology to offer the first autologous cell therapy for Parkinson’s disease—while others in the space have pursued allogeneic routes, or therapies derived from donors other than the patient.
“We can say without any equivocation that we can produce the population of cells necessary to transplant, and in a short enough period of time to have a potential beneficial impact on the evolution of the disease,” said Federoff, who has also served as chair of the NIH’s Recombinant DNA Advisory Committee and helped lead the U.S. Parkinson’s Disease Gene Therapy Study Group.
“We envisage that this will set back the clock on patients who have Parkinson’s, unlike any other therapy that we know of,” he told FierceMedTech in an interview.
“We anticipate that they will manufacture and release dopamine in a manner that is consistent with synaptic neurotransmission and the process of communicating from cell-to-cell,” said Federoff. “They will take up dopamine from synapses when it has done its business, bring it back into the cell, and prepare it for another synaptic release.”
“These are not just dopamine pumps, they’re real neurons,” added Loring. “They will genuinely replace the cells that have been lost in every way.
“Aspen plans to pursue two courses of therapy, for the two major types of Parkinson’s disease. Their lead candidate is for idiopathic, or sporadic Parkinson’s, while their second is a CRISPR-edited version of the therapy designed to address one of the disease’s most common genetic mutations, linked to about 5% of cases.
“This would not only aim to restart dopamine production in this orphan indication, but also restore the damaged enzyme GBA, which is seen as an underlying cause. Federoff and Loring expect their sequencing-based quality check system will also help catch any off-target edits linked to the use of CRISPR-Cas9.
“After it receives its go-ahead from the FDA, Aspen plans to hit the ground running, enrolling at least 176 participants in a phase 1/2 study that includes a randomized stage to determine clinical benefits.”
Full article: fiercebiotech.com/medtech/b...